Goldman, J., Angevin, E., Strickler, J., Camidge, D. R., Heist, R., Morgensztern, D., … Kelly, K. (2017). MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC. In Journal of Thoracic Oncology (Vol. 12, pp. S1805–S1806). Elsevier BV. https://doi.org/10.1016/j.jtho.2017.09.458

Goldman, J., E. Angevin, J. Strickler, D. R. Camidge, R. Heist, D. Morgensztern, M. Barve, et al. “MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC.” In Journal of Thoracic Oncology, 12:S1805–6. Elsevier BV, 2017. https://doi.org/10.1016/j.jtho.2017.09.458.

Goldman J, Angevin E, Strickler J, Camidge DR, Heist R, Morgensztern D, et al. MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC. In: Journal of Thoracic Oncology. Elsevier BV; 2017. p. S1805–6.

Goldman, J., et al. “MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC.” Journal of Thoracic Oncology, vol. 12, no. 11, Elsevier BV, 2017, pp. S1805–06. Crossref, doi:10.1016/j.jtho.2017.09.458.

Goldman J, Angevin E, Strickler J, Camidge DR, Heist R, Morgensztern D, Barve M, Yue H, Beaulieu J, Motwani M, Afar D, Naumovski L, Kelly K. MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC. Journal of Thoracic Oncology. Elsevier BV; 2017. p. S1805–S1806.